scholarly journals Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines

2016 ◽  
Vol 9 (1) ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Sterzyńska ◽  
Katarzyna Zaorska ◽  
Patrycja Sosińska ◽  
Andrzej Klejewski ◽  
...  
Toxins ◽  
2019 ◽  
Vol 11 (4) ◽  
pp. 237 ◽  
Author(s):  
Okiemute Rosa Johnson-Ajinwo ◽  
Alan Richardson ◽  
Wen-Wu Li

Ovarian cancer ranks amongst the deadliest cancers in the gynaecological category of cancers. This research work aims to evaluate in vitro anti-ovarian cancer activities and identify phytochemical constituents of a rarely explored plant species—Rutidea parviflora DC. The aqueous and organic extracts of the plant were evaluated for cytotoxicity using sulforhodamine B assay in four ovarian cancer cell lines and an immortalized human ovarian epithelial (HOE) cell line. The bioactive compounds were isolated and characterized by gas/liquid chromatography mass spectrometry and nuclear magnetic resonance spectroscopy. Caspase 3/7 activity assay, western blotting and flow cytometry were carried out to assess apoptotic effects of active compounds. The extracts/fractions of R. parviflora showed promising anti-ovarian cancer activities in ovarian cancer cell lines. A principal cytotoxic alkaloid was identified as palmatine whose IC50 was determined as 5.5–7.9 µM. Palmatine was relatively selective towards cancer cells as it was less cytotoxic toward HOE cells, also demonstrating interestingly absence of cross-resistance in cisplatin-resistant A2780 cells. Palmatine further induced apoptosis by increasing caspase 3/7 activity, poly-ADP-ribose polymerase cleavage, and annexin V and propidium iodide staining in OVCAR-4 cancer cells. Our studies warranted further investigation of palmatine and R. parviflora extracts in preclinical models of ovarian cancer.


2016 ◽  
Vol 12 (3) ◽  
pp. 2065-2070 ◽  
Author(s):  
Jin Liu ◽  
Xiaohua Wu ◽  
Hongmei Liu ◽  
Yijuan Liang ◽  
Xinping Gao ◽  
...  

2013 ◽  
Vol 67 (3) ◽  
pp. 240-245 ◽  
Author(s):  
Radosław Januchowski ◽  
Piotr Zawierucha ◽  
Małgorzata Andrzejewska ◽  
Marcin Ruciński ◽  
Maciej Zabel

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Wojtowicz ◽  
Patrycja Sujka-Kordowska ◽  
Małgorzata Andrzejewska ◽  
Maciej Zabel

Ovarian cancer is the leading cause of death among gynaecological malignancies. Multiple drug resistance makes cancer cells insensitive to chemotherapy. In this study, we developed six primary ovarian cancer cell lines (W1MR, W1CR, W1DR, W1VR, W1TR, and W1PR) resistant to drugs such as methotrexate, cisplatin, doxorubicin, vincristine, topotecan, and paclitaxel. A chemosensitivity assay MTT test was performed to assess drug cross-resistance. Quantitative real-time polymerase chain reaction and Western blot were also performed to determine mRNA and protein expression of genes involved in chemoresistance. We observed high cross-resistance to doxorubicin, vincristine, and paclitaxel in the cell lines resistant to these agents. We also found a significant correlation between resistance to these drugs and increased expression of P-gp. Two different mechanisms of topotecan resistance were observed in the W1TR and W1PR cell lines. We did not observe any correlation between MRP2 transcript and protein levels. Cell lines resistant to agents used in ovarian cancer treatment remained sensitive to methotrexate. The main mechanisms of drug resistance were due to P-gp expression in the doxorubicin, vincristine, and paclitaxel resistant cell lines and BCRP expression in the topotecan resistant cell line.


2021 ◽  
Vol 9 (3) ◽  
pp. 138-147
Author(s):  
Marta Nowacka ◽  
Barbara Ginter-Matuszewska ◽  
Monika Świerczewska ◽  
Michał Nowicki ◽  
Maciej Zabel ◽  
...  

Abstract Resistance to chemotherapy is the main obstacle in contemporary ovarian cancer treatment. The aim of this study was the evaluation of expression of HERC5, IFIH1, SAMD4, MCTP1 and SEMA3A mRNA and assessment their role in resistance to cisplatin, paclitaxel, doxorubicin and topotecan in seven ovarian cancer cell lines. MTT assay was used in resistance assessment. Quantitative polymerase chain reaction was performed to measure the expression levels of the genes. We observed different levels of resistance among cell lines. The resistance was not related to the expression of drug transporters genes. The expression of HERC5 and IFIH1 genes was upregulated, and the expression of SEMA3A gene was downregulated. Expression of SAMD4 was upregulated in PEA1, PEA2, and PEO23 cell lines, and expression of MCTP1 was downregulated in A2780, PEA2, and PEO23 cell lines. Upregulation of HERC5, IFIH1, and SAMD4 and downregulation of SEMA3A and MCTP1 in TOP-resistant ovarian cancer cell lines may suggest some role of those genes in topotecan resistance development.


2015 ◽  
Vol 149 ◽  
pp. 45-48 ◽  
Author(s):  
Marina Stukova ◽  
Matthew D. Hall ◽  
Samantha D. Tsotsoros ◽  
James P. Madigan ◽  
Nicholas P. Farrell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document